Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Arcus Biosciences (RCUS) Asset Writedowns and Impairment (2024)

Arcus Biosciences has reported Asset Writedowns and Impairment over the past 1 years, most recently at $20.0 million for Q1 2024.

Quarterly results put Asset Writedowns and Impairment at $20.0 million for Q1 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was $20.0 million (changed N/A YoY), and the annual figure for FY2024 was $20.0 million, changed.
Asset Writedowns and Impairment for Q1 2024 was $20.0 million at Arcus Biosciences.
Over the last five years, Asset Writedowns and Impairment for RCUS hit a ceiling of $20.0 million in Q1 2024 and a floor of $20.0 million in Q1 2024.